Barcelona – PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical update of OVX836, a novel Universal Type A influenza vaccine candidate ”.
Archives de l’auteur : Marianne Duparc
IDWeek 2023
Boston, MA – PosterAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a poster.
17th Vaccine Congress
Glasgow – PostersAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 and additional data on the cross-reactivity of the immune responses as part of two posters.
9th ESWI 2023
Valencia – PostersDelphine Guyon-Gellin, Chief Business Development Officer of Osivax, to provide a clinical update on OVX836 as part of a poster entitled « Co-Administration of OVX836, NP-Based Universal Influenza Vaccine Candidate, with Conventional HA-Based Influenza Vaccine: Results of Phase 2a Clinical Trial ». Florence Nicolas, Chief Development Officer and Co-founder of Osivax, to provide additional data …
Vers un vaccin efficace contre tous les variants du SARS-CoV2 ?
Les quatre domaines d’excellence de la French Tech
Universal Flu Vaccine Candidate Shows Promise in Mid-Stage Trial — Efficacy in range of NIH target, exploratory analysis finds
Osivax Announces Publication in The Lancet Infectious Diseases of Phase 2a Data for Broad-Spectrum Influenza Vaccine Candidate, OVX836
Osivax Announces Publication in The Lancet Infectious Diseases of Phase 2a Data for Broad-Spectrum Influenza Vaccine Candidate, OVX836 OVX836 demonstrated positive safety and immunogenicity data across three dose levels A notable signal of protection of 84% was observed against symptomatic influenza infection Lyon, France – July 28, 2023 – Osivax, a a biopharmaceutical company developing vaccines to provide …
OVX-033 vaccine exhibits broad protection against SARS-CoV-2 in preclinical models
Osivax Publishes Preclinical Data for Sarbecovirus Vaccine Candidate, OVX033 in Frontiers in Immunology
Osivax Publishes Preclinical Data for Sarbecovirus Vaccine Candidate, OVX033in Frontiers in Immunology Evidence of cross-protection against multiple SARS-CoV-2 variants of concern observed in hamster challenge model Lyon, France – July 06, 2023 – Osivax, a a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced the publication of promising preclinical …